Federal Register / Vol. 78, No. 226 / Friday, November 22, 2013 / Notices 70047 

2See 78 FR 47317 (60-Day Federal Register 

Notice) and 78 FR 65649 (extended comment period 

until Nov. 8, 2013). 

3Staff has derived an hourly wage rate ($250/ 

hour) for legal professionals based upon industry 

knowledge. The wage rates for legal support 

workers ($24.57) and for clerical support ($16.54) 

used in this Notice are based on recent data from 

the Bureau of Labor Statistics National 

Compensation Survey (Mar. 29, 2013), available at 

http://www.bls.gov/news.release/ocwage.htm. 

information that must appear in a 

written warranty on a consumer product 

costing more than $15. The Rule tracks 

Section 102(a) of the Warranty Act, 

specifying information that must appear 

in the written warranty and, for certain 

disclosures, mandates the exact 

language that must be used. Neither the 

Warranty Rule nor the Act requires that 

a manufacturer or retailer warrant a 

consumer product in writing, but if they 

choose to do so, the warranty must 

comply with the Rule. 

On August 5, 2013, the Commission 

sought comment on the Rule’s 

information collection requirements.2

The Commission did not receive any 

comments. 

As required by OMB regulations, 5 

CFR Part 1320, the FTC is providing this 

second opportunity for public comment. 

Likely Respondents: Manufacturers of 

consumer products. 

Estimated Annual Hours Burden: 

116,128 hours (derived from estimated 

14,516 manufacturers × 8 hours of 

burden per year). 

Estimated Annual Cost Burden: 

$15,710,000, rounded to the nearest 

thousand (which is derived from 

$14,516,000 for legal professionals + 

$713,316 for legal support + $480,189 

for clerical workers).3

• Legal Professionals: (0.5) (116,128 

hours) ($250/hour) = $14,516,000 

• Legal Support: (0.25) (116,128 

hours) ($24.57/hour) = $713,316 

• Clerical Workers: (0.25) (116,128 

hours) ($16.54/hour) = $480,189 

Request for Comment 

You can file a comment online or on 

paper. For the Commission to consider 

your comment, we must receive it on or 

before December 23, 2013. Write 

‘‘Warranty Rules: Paperwork Comment, 

FTC File No. P044403’’ on your 

comment. Your comment—including 

your name and your state—will be 

placed on the public record of this 

proceeding, including, to the extent 

practicable, on the public Commission 

Web site, at http://www.ftc.gov/os/ 

publiccomments.shtm. As a matter of 

discretion, the Commission tries to 

remove individuals’ home contact 

information from comments before 

placing them on the Commission Web 

site. 

Because your comment will be made 

public, you are solely responsible for 

making sure that your comment does 

not include any sensitive personal 

information, such as anyone’s Social 

Security number, date of birth, driver’s 

license number or other state 

identification number or foreign country 

equivalent, passport number, financial 

account number, or credit or debit card 

number. You are also solely responsible 

for making sure that your comment does 

not include any sensitive health 

information, like medical records or 

other individually identifiable health 

information. In addition, do not include 

any ‘‘[t]rade secret or any commercial or 

financial information which is * * * 

privileged or confidential,’’ as discussed 

in Section 6(f) of the FTC Act, 15 U.S.C. 

46(f), and FTC Rule 4.10(a)(2), 16 CFR 

4.10(a)(2). In particular, do not include 

competitively sensitive information 

such as costs, sales statistics, 

inventories, formulas, patterns, devices, 

manufacturing processes, or customer 

names. 

If you want the Commission to give 

your comment confidential treatment, 

you must file it in paper form, with a 

request for confidential treatment, and 

you are required to follow the procedure 

explained in FTC Rule 4.9(c), 16 CFR 

4.9(c). Your comment will be kept 

confidential only if the FTC General 

Counsel, in his or her sole discretion, 

grants your request in accordance with 

the law and the public interest. 

Postal mail addressed to the 

Commission is subject to delay due to 

heightened security screening. As a 

result, we encourage you to submit your 

comment online, or to send it to the 

Commission by courier or overnight 

service. To make sure that the 

Commission considers your online 

comment, you must file it at https:// 

ftcpublic.commentworks.com/ftc/ 

consumerwarrantypra2, by following 

the instructions on the web-based form. 

If this Notice appears at http:// 

www.regulations.gov, you also may file 

a comment through that Web site. 

If you file your comment on paper, 

write ‘‘Warranty Rules: Paperwork 

Comment, FTC File No. P044403’’ on 

your comment and on the envelope, and 

mail or deliver it to the following 

address: Federal Trade Commission, 

Office of the Secretary, Room H–113 

(Annex J), 600 Pennsylvania Avenue 

NW., Washington, DC 20580. If possible, 

submit your paper comment to the 

Commission by courier or overnight 

service. 

Visit the Commission Web site at 

http://www.ftc.gov to read this Notice. 

The FTC Act and other laws that the 

Commission administers permit the 

collection of public comments to 

consider and use in this proceeding as 

appropriate. The Commission will 

consider all timely and responsive 

public comments that it receives on or 

before December 23, 2013. You can find 

more information, including routine 

uses permitted by the Privacy Act, in 

the Commission’s privacy policy, at 

http://www.ftc.gov/ftc/privacy.shtm. 

Comments on the information 

collection requirements subject to 

review under the PRA should also be 

submitted to OMB. If sent by U.S. mail, 

address comments to: Office of 

Information and Regulatory Affairs, 

Office of Management and Budget, 

Attention: Desk Officer for the Federal 

Trade Commission, New Executive 

Office Building, Docket Library, Room 

10102, 725 17th Street NW., 

Washington, DC 20503. Comments sent 

to OMB by U.S. postal mail, however, 

are subject to delays due to heightened 

security precautions. Thus, comments 

instead should be sent by facsimile to 

(202) 395–5167. 

David C. Shonka, 

Principal Deputy General Counsel. 

[FR Doc. 2013–27982 Filed 11–21–13; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[CDC–2013–0022; Docket Number NIOSH 

153–B] 

Request for the Technical Review of 25 

Draft Skin Notation Assignments and 

Skin Notation Profiles 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Request for comments. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) is 

conducting a public review of the draft 

skin notations and supporting technical 

documents entitled, Skin Notations 

Profiles, for 25 chemicals. NIOSH is 

requesting technical reviews of the draft 

Skin Notation Profiles. This review is 

consistent with the process used for the 

publication of the first 20 Skin Notation 

Profiles, Docket Number NIOSH 153–A 

[http://www.cdc.gov/niosh/docket/

archive/docket153A.html]. To facilitate 


emcdonald on DSK67QTVN1PROD with NOTICES
70048 Federal Register / Vol. 78, No. 226 / Friday, November 22, 2013 / Notices 

the review of these documents, NIOSH 

requests that the following questions be 

taken into consideration for each Skin 

Notation Profile: 

1. Does this document clearly outline 

the systemic health hazards associated 

with exposures of the skin to the 

chemical? If not, what specific 

information is missing from the 

document? 

2. If the SYS or SYS (FATAL) 

notations are assigned, are the rationale 

and logic behind the assignment clear? 

If not assigned, is the logic clear why it 

was not (e.g., insufficient data, no 

identified health hazard)? 

3. Does this document clearly outline 

the direct (localized) health hazards 

associated with exposures of the skin to 

the chemical? If not, what specific 

information is missing from the 

document? 

4. If the DIR, DIR (IRR), or DIR (COR) 

notations are assigned, are the rationale 

and logic behind the assignment clear? 

If not assigned, is the logic clear why it 

was not (e.g., insufficient data, no 

identified health hazard)? 

5. Does this document clearly outline 

the immune-mediated responses 

(allergic response) health hazards 

associated with exposures of the skin to 

the chemical? If not, what specific 

information is missing from the 

document? 

6. If the SEN notation is assigned, are 

the rationale and logic behind the 

assignment clear? If not assigned, is the 

logic clear why it was not (e.g., 

insufficient data, no identified health 

hazard)? 

7. If the ID (SK) or SK were assigned, 

are the rationale and logic outlined 

within the document? 

8. Are the conclusions supported by 

the data? 

9. Are the tables clear and 

appropriate? 

10. Is the document organized 

appropriately? If not, what 

improvements are needed? 

11. Are you aware of any scientific 

data reported in governmental 

publications, databases, peer-reviewed 

journals, or other sources that should be 

included within this document? 

DATES: Electronic or written comments 

on the 25 documents contained within 

Group B must be received on or before 

January 21, 2014. 

ADDRESSES: You may submit comments, 

identified by CDC–2013–0022 and 

docket number NIOSH 153–B, by any of 

the two following methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: NIOSH Docket Office, Robert 

A. Taft Laboratories, MS–C34, 4676 

Columbia Parkway, Cincinnati, OH 

45226. 

All information received in response 

to this notice must include the agency 

name and docket number [CDC–2013– 

0022; NIOSH 153–B]. All relevant 

comments received will be posted 

without change to www.regulations.gov, 

including any personal information 

provided. All electronic comments 

should be formatted as Microsoft Word. 

To view this notice and related 

materials, visit www.regulations.gov and 

enter CDC–2013–0022 in the search 

field and click ‘‘search.’’ 

All information received in response 

to this notice will be available for public 

examination and copying at the NIOSH 

Docket Office, 4676 Columbia Parkway, 

Cincinnati, Ohio 45226. 

FOR FURTHER INFORMATION CONTACT: 

Naomi Hudson, NIOSH, Robert A. Taft 

Laboratories, MS–C32, 4676 Columbia 

Parkway, Cincinnati, OH 45226, 

telephone (513) 533–8388 or G. Scott 

Dotson, NIOSH, Robert A. Taft 

Laboratories, MS–C32, 4676 Columbia 

Parkway, Cincinnati, OH 45226, 

telephone (513) 533–8540. 

SUPPLEMENTARY INFORMATION: In 2009, 

NIOSH published Current Intelligence 

Bulletin (CIB) 61—A Strategy for 

Assigning New NIOSH Skin Notations 

[NIOSH 2009–147; http://www.cdc.gov/ 

niosh/docs/2009-147/pdfs/2009- 

147.pdf]. The CIB presents a strategic 

framework that is a form of hazard 

identification that has been designed to 

do the following: 

1. Ensure that the assigned skin 

notations reflect the contemporary state 

of scientific knowledge 

2. Provide transparency behind the 

assignment process 

3. Communicate the hazards of 

chemical exposures of the skin 

4. Meet the needs of health 

professionals, employers, and other 

interested parties in protecting workers 

from chemical contact with the skin. 

This strategy involves the assignment 

of multiple skin notations for 

distinguishing systemic (SYS), direct 

(DIR), and sensitizing (SEN) effects 

caused by exposure of skin (SK) to 

chemicals. Chemicals that are highly or 

extremely toxic and may be potentially 

lethal or life-threatening following 

exposures of the skin are designated 

with the systemic subnotation (FATAL). 

Potential irritants and corrosive 

chemicals are indicated by the direct 

effects subnotations (IRR) and (COR), 

respectively. Thus with the new 

strategy, chemicals labeled as SK: SYS 

are recognized to contribute to systemic 

toxicity through dermal absorption. 

Chemicals assigned the notation SK: 

SYS (FATAL) have been identified as 

highly or extremely toxic and have the 

potential to be lethal or life-threatening 

following acute contact with the skin. 

Substances identified to cause direct 

effects (i.e., damage or destruction) to 

the skin limited to or near the point of 

contact are labeled SK: DIR, and those 

resulting in skin irritation and corrosion 

at the point of contact are labeled as SK: 

DIR (IRR) and SK: DIR (COR), 

respectively. The SK: SEN notation is 

used for substances identified as 

causing or contributing to allergic 

contact dermatitis (ACD) or other 

immune-mediated responses, such as 

airway hyper reactivity (asthma). 

Candidate chemicals may be assigned 

more than one skin notation when they 

are identified to cause multiple effects 

resulting from skin exposure. For 

example, if a chemical is identified as 

corrosive and also contributes to 

systemic toxicity, it will be labeled as 

SK: SYS–DIR (COR). When scientific 

data for a chemical indicate that skin 

exposure does not produce systemic, 

direct, or sensitizing effects, the 

compound will be assigned the notation 

(SK). The ID(SK) notation is assigned to 

indicate that insufficient data on the 

health hazards associated with skin 

exposure to a substance exist at the time 

of the review to determine whether the 

chemical has the potential to act as a 

systemic, direct, or sensitizing agent. 

The ND notation indicates that a 

chemical has not been evaluated by the 

strategy outlined in this CIB and that the 

health hazards associated with skin 

exposure are unknown. 

Historically, skin notations have been 

published in the NIOSH Pocket Guide to 

Chemical Hazards [NIOSH 2005–149]. 

This practice will continue with the 

NIOSH skin notation assignments for 

each evaluated chemical being 

integrated as they become available. A 

support document called a Skin 

Notation Profile has been developed for 

each evaluated chemical. NIOSH 

submitted the first group of Skin 

Notation Profiles for external review in 

2010 [75 FR 22148] and published the 

finalized reports in 2011 [http://

www.cdc.gov/niosh/topics/skin/skinnotation_profiles.html]. The Skin 

Notation Profile for a chemical is 

intended to provide information 

supplemental to the skin notation, 

including a summary of all relevant data 

used to aid in determining the hazards 

associated with skin exposures. 

NIOSH seeks comments on the draft 

skin notation assignments and Skin 

Notation Profiles for 25 chemicals. The 

draft Skin Notation Profiles were 

developed to provide the scientific 

rationale behind the hazard-specific 


emcdonald on DSK67QTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 226 / Friday, November 22, 2013 / Notices 70049 

skin notation (SK) assignments for the 

following chemicals: 

Document Substance(s) 

B–01 ...... Allyl glycidyl ether (CAS# 108– 

92–3). 

B–02 ...... 2-Diethylaminoethanol (CAS# 

100–37–8). 

B–03 ...... Methyl isocyanate (CAS# 624– 

83–9). 

B–04 ...... 2-Ethoxyethyl acetate (CAS# 

111–15–9). 

B–05 ...... Propargyl alcohol (CAS# 107–19– 

7). 

B–06 ...... Ethyl acrylate (CAS# 140–88–5). 

B–07 ...... Isophorone diisocyanate (CAS# 

4098–71–9). 

B–08 ...... Nitrobenzene (CAS# 98–95–3). 

B–09 ...... Phenylhydrazine (CAS# 100–63– 

0). 

B–10 ...... 2-Mercaptobenzothiazole (CAS# 

149–30–4). 

B–11 ...... Aniline (CAS# 62–53–3). 

B–12 ...... Captafol (CAS# 2425–06–1). 

B–13 ...... Dinitro-o-cresol (CAS# 534–52– 

1). 

B–14 ...... Aldrin (CAS# 309–00–2). 

B–15 ...... Dieldrin (CAS# 60–57–1). 

B–16 ...... Parathion (CAS# 56–38–2). 

B–17 ...... Nicotine (CAS# 54–11–5). 

B–18 ...... Azinphos-methyl (CAS# 86–50– 

0). 

B–19 ...... Endrin (CAS# 72–20–8). 

B–20 ...... Methyl parathion (CAS# 298–00– 

0). 

B–21 ...... Phorate (CAS# 298–02–2). 

B–22 ...... Phosdrin (CAS# 7786–34–7). 

B–23 ...... TEDP (CAS# 3689–24–5). 

B–24 ...... TEPP (CAS# 107–49–3). 

B–25 ...... Chlordane (CAS# 57–74–9). 

Each Skin Notation Profile provides a 

detailed summary of the health hazards 

of skin contact and rationale for the 

proposed SK assignment with the 

chemical(s)-of-interest. 

Dated: November 14, 2013. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2013–28019 Filed 11–21–13; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 78 FR 63982–63983, 

dated October 25, 2013) is amended to 

reorganize the Office of Surveillance, 

Epidemiology and Laboratory Services, 

Centers for Disease Control and 

Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

Delete in its entirety the titles and 

functional statements for the Office of 

Surveillance, Epidemiology and 

Laboratory Services (CP) and insert the 

following: 

Office of Public Health Scientific 

Services (CP). The Office of Public 

Health Scientific Services (OPHSS) is to 

lead, promote, and facilitate science, 

standards and policies to reduce the 

burden of diseases in the United States 

and globally. 

Office of the Director (CPA). (1) 

Serves as the principal advisor to the 

Centers for Disease Control and 

Prevention (CDC) Director on 

informatics issues; (2) assists the CDC 

Director in formulating and 

communicating strategic initiatives and 

policies involving health statistics, 

informatics, surveillance, epidemiology 

and laboratory practices; (3) represents 

the CDC Director externally on key 

informatics issues; (4) provides strategic 

leadership to the National Center for 

Health Statistics (NCHS) and the Center 

for Surveillance, Epidemiology and 

Laboratory Services (CSELS); (5) ensures 

agency-wide strategic approaches to 

informatics, surveillance, data access, 

workforce development and laboratory 

practices; (6) identifies approaches for 

increasing the use of electronic health 

records (EHRs) as part of an integrated 

strategy for public health surveillance; 

(7) leads efforts to improve public 

health data access and analytical 

methods; (8) leads the development of 

an efficient, sustainable and integrated 

network of public health laboratories; 

(9) leads efforts to prepare the public 

health workforce to meet present and 

anticipate future challenges; (10) 

facilitates relevant and meaningful 

collaborations across NCHS and CSELS; 

and (11) ensures the timely availability 

of statistical health information. 

Health Information Technology and 

Surveillance Strategy Unit (CPA3). As 

the OPHSS’ primary focal point, the 

unit leads collaborative activities at 

multiple levels and with multiple 

partners to ensure CDC maintains a 

leadership role in the development of 

strategy, policy, future solutions and 

issues relating to improvements in 

integrating health information 

technology (HIT), public health 

surveillance and biosurveillance 

strategies with the ultimate goal of 

strengthening public health. This unit: 

(1) Leads and manages a network of 

intersects with CDC’s key state, 

territorial, local and tribal (STLT) 

partner organizations and their members 

through routine work groups and 

collaboration forums to collaboratively 

develop solutions in the areas of HIT, 

public health surveillance and 

biosurveillance to strengthen public 

health at the federal and STLT levels; 

(2) leads and manages CDC’s 

interactions with other federal agencies 

to ensure CDC maintains its leadership 

role in the areas of HIT, public health 

surveillance and biosurveillance, 

including representing CDC on the 

Department of Homeland Security’s 

National Biosurveillance Integration 

Oversight Committee, the White House 

National Security Staff’s SubInteragency Policy Committee on 

Biosurveillance and management of a 

federal Biosurveillance Work Group 

resulting in CDC’s coordinated input 

into federal government wide policies, 

initiatives and products; (3) serves as 

the primary point of contact for CDC 

health HIT activities with the Office of 

the National Coordinator for Health 

Information Technology (ONC) and the 

Centers for Medicare and Medicaid 

Services; (4) leads and manages a 

network of intersects within CDC to 

ensure initiatives and activities are 

coordinated and complimentary in the 

areas of HIT, public health surveillance 

and biosurveillance to include the 

management of the CDC’s EHR Forum, 

the Biosurveillance Leadership Team, 

and the OPHSS/Office of Infectious 

Diseases monthly leadership meeting; 

(5) leads the work, education, 

communication and coordinated 

activities necessary to ensure CDC is 

involved in and contributes to 

electronic health information exchange, 

specifically, Meaningful Use (MU) 

through the convening of EHR/MU 

advisory groups, the provision of 

appropriate technical assistance to CDC 

programs and STLT partners, the 

convening of national communities of 

practice (with ONC), and the education 

of CDC programs on EHR/MU; (6) 

maintains leadership and consultation 

to various federal advisory committees; 

and (7) maintains and utilizes the 

National Public Health Surveillance and 

Biosurveillance Registry for Human 

Health, which catalogs CDC 

surveillance-related systems, programs, 

collaboratives, registries, and tools, and 

provides reports from the Registry to 

support and promote coordinated 

actions and efficiencies in surveillance 

activities throughout the Agency. 


emcdonald on DSK67QTVN1PROD with NOTICES